OBJECTIVES The aim of this report is to characterize the impact of balloon aortic valvuloplasty (BAV) in patients not undergoing aortic valve replacement in the PARTNER (Placement of AoRtic TraNscathetER Valves) trial.
A ortic stenosis (AS) is a common condition among the elderly and is associated with poor survival without surgery once symptoms develop (1, 2) . In addition, patients with severe AS experience progressive symptoms with reduced functional status and quality of life (QOL). Despite the success of surgical valve replacement in alleviating symptoms, improving functional status, and extending survival (3, 4) , a substantial minority of patients with severe AS remain untreated due to prohibitive surgical risk (5, 6) . One-year mortality rates may exceed 50% in these patients (7) .
After the first human report in 2002 (8) , transcatheter aortic valve replacement (TAVR) has emerged as a less invasive treatment option for patients with AS and a high or unacceptable surgical risk (9) (10) (11) . The PARTNER (Placement of AoRtic TraNscathetER Valves) trial demonstrated that for patients who are not suitable candidates for surgery, TAVR led to a 20% absolute reduction in all-cause mortality at 1 year compared with standard therapy, and this benefit was sustained and actually more pronounced when patients were followed for 2 years (12) . Beyond its mortality benefit, TAVR led to improvement in symptoms, functional status, and QOL, which may be more important than the survival benefit for these elderly patients (13) .
The PARTNER trial was the first randomized trial with a collection of outcome adjudicated data on inoperable patients, allowing one to study the outcomes of unoperated-on patients with severe symptomatic AS. Although balloon aortic valvuloplasty (BAV) has been used for palliation as well as a bridge to surgical aortic valve replacement (AVR), the impact of BAV has not been studied with independent adjudication compared with standard medical therapy (14) (15) (16) . The standard therapy arm of the PARTNER trial provides an opportunity to better understand the role of BAV in inoperable patients. In this report, we attempt to characterize the outcomes of standard therapy in patients not undergoing TAVR with a special focus on the role of BAV.
METHODS
STUDY DESIGN. The design and initial results of the PARTNER trial (Cohort B) were published previously (17) . In brief, the PARTNER program enrolled patients with severe AS, New York Heart Association functional class II, III, or IV heart failure symptoms, and prohibitively high surgical risk based on the Society for Thoracic Surgeons (STS) risk score and qualifying assessments by the heart team. Patients included in the present study were not considered to be suitable candidates for cardiac surgery because of coexisting medical conditions associated with a predicted probability of death or permanent disability $50%, as determined by at least 2 surgical investigators and reaffirmed by the study's executive committee. These patients were then randomized to TAVR, using the Edwards SAPIEN heart valve system (Edwards Lifesciences, Irvine, California), or standard medical care, which often included BAV at the discretion of the investigators.
There was no specific time stipulated in the protocol for TAVR after randomization, although treatment within 2 weeks of randomization was encouraged.
The PARTNER trial was funded by Edwards Lifesciences and designed collaboratively by the steering committee and the sponsor. The study was approved by each participating site's Institutional Review Board, and all patients provided written informed consent. All events were independently adjudicated, and echocardiograms were interpreted by a core laboratory. The current analysis was carried out by academic investigators at the study sites and by the Health Economics and Technology Assessment Group 
RESULTS
PATIENT POPULATION. In the PARTNER Cohort B study, 179 inoperable patients were randomized to standard treatment without TAVR. At the time of enrollment, the majority of the patients were on contemporary treatment for heart failure: diuretics, 80%; beta-blockers, 62%; statins, 61%; angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 41%; aspirin, 59%; and warfarin, 24%. Table 2 ). Patients undergoing BAV had more severe congestive heart failure symptoms and a higher logistic EuroSCORE.
However, other characteristics including STS score, echocardiographic characteristics, and QOL parameters were not different between these 2 groups. There were 53 patients who had BAV past 30 days, and 12 of these had more than 1 such BAV. of patients, respectively, and after the first BAV, the counts were 9%, 32%, 55%, 16%, and 2%, respectively. No crossovers to TAVR were allowed after BAV for severe aortic regurgitation. All outcomes of the 3 groups of patients are reported in Table 4 .
CLINICAL OUTCOMES. There was meaningful improvement in heart failure symptoms in the BAV group compared with the no BAV group, as demonstrated by improvement in NYHA functional class ( Figure 1 ). There was improvement in QOL parameters when paired comparisons were made between baseline and 30 days and 6 months in the BAV group, but this effect was lost at 12-month follow-up ( (Figure 2 
DISCUSSION
There are several major observations that can be made from the detailed analysis of these prospectively collected data. First, the outcome of patients with severe symptomatic AS who do not undergo AVR is poor. Second, BAV improves outcomes in these inoperable patients for a few months. Third, repeat valvuloplasties are less effective than the first one. Abbreviations as in Table 1 . NA ¼ not available; other abbreviations as in Table 1 .
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Impact of Aortic Valvuloplasty These data also provide some insight beyond balloon valvuloplasty in these inoperable patients. A few patients randomized to standard therapy did undergo surgery, and they had poor outcomes, especially compared with those randomized to undergo TAVR in whom the 1-year mortality rate was 31% (17) .
Patients who underwent apico-descending aorta conduit or surgical AVR had poor outcomes, with 33% and 27% mortality rates in the first 30 days, respectively.
There are several implications of this analysis for clinical practice. BAV can improve symptoms and QOL, although early bridging to AVR is essential for a better outcome. QOL can be improved to some extent with BAV for w6-month duration. 
